Patient in trial of Astex drug achieves complete remission, Pediatrics says
In a case report published online December 24 by Pediatrics, the official journal of the American Academy of Pediatrics, a patient with a persistent tumor in his bone marrow after completion of standard therapy for neuroblastoma is described to have achieved a complete remission after 3 cycles of decitabine and vaccine therapy. The patient is involved in a phase 1 study of the experimental regimen, according to the case report. Decitabine, trade name Dacogen, is licensed by Astex Pharmaceuticals (ASTX), to Eisai. In early morning trade, shares of Astex rose 19c, or 6.88%, to $2.95.
